Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2023-03-09 4:17 pm Purchase | 13G | Phathom Pharmaceuticals, Inc. PHAT | Carlyle Group Inc. CG | 2,935,106 6.7% | 2,935,106 (New Position) | View |
| 2023-02-23 4:15 pm Purchase | 13D | Spruce Biosciences, Inc. SPRB | Carlyle Group Inc. CG | 3,734,518 9.2% | 1,932,000 (+107.18%) | View |
| 2023-02-13 2:49 pm Sale | 13G | The Carlyle Group Inc. CG | Capital World Investors | 2,217,000 0.6% | -17,098,259 (-88.52%) | View |
| 2023-02-10 4:16 pm Purchase | 13G | HilleVax, Inc. HLVX | Carlyle Group Inc. CG | 1,838,486 5.5% | 1,838,486 (New Position) | View |
| 2023-02-10 4:16 pm Sale | 13G | ZoomInfo Technologies Inc. ZI | Carlyle Group Inc. CG | 36,662,469 9.1% | -7,579,513 (-17.13%) | View |
| 2023-02-10 4:14 pm Purchase | 13G | Vaxcyte, Inc. PCVX | Carlyle Group Inc. CG | 2,070,724 2.6% | 2,070,724 (New Position) | View |
| 2023-02-10 4:02 pm Sale | 13G | The Carlyle Group Inc. CG | Rubenstein David M. | 29,249,644 8.1% | -2,000,000 (-6.40%) | View |
| 2023-02-09 10:54 am Purchase | 13G | The Carlyle Group Inc. CG | VANGUARD GROUP INC | 24,952,869 6.86% | 2,129,460 (+9.33%) | View |
| 2023-02-08 2:29 pm Purchase | 13G | The Carlyle Group Inc. CG | MORGAN STANLEY MS | 23,412,646 6.4% | 5,188,324 (+28.47%) | View |
| 2023-01-31 4:15 pm Purchase | 13D | Jasper Therapeutics, Inc. JSPR | Carlyle Group Inc. CG | 8,761,891 8% | 3,133,333 (+55.67%) | View |
| 2023-01-23 5:15 pm Purchase | 13D | Vertical Capital Income Fund VCIF | Carlyle Group Inc. CG | 3,718,256 35.8% | 3,718,256 (New Position) | View |
| 2022-12-20 4:30 pm Sale | 13D | Soleno Therapeutics, Inc. SLNO | Carlyle Group Inc. CG | 0 0% | -18,368,564 (Position Closed) | View |
| 2022-08-29 5:27 pm Purchase | 13G | MKS Instruments, Inc. MKSI | Carlyle Group Inc. CG | 8,482,732 12.8% | 8,482,732 (New Position) | View |
| 2022-08-11 5:03 pm Purchase | 13D | Exicure, Inc. XCUR | Carlyle Group Inc. CG | 285,430 5.7% | 285,430 (New Position) | View |
| 2022-08-11 5:01 pm Purchase | 13D | Vera Therapeutics, Inc. VERA | Carlyle Group Inc. CG | 2,970,156 11.1% | 2,970,156 (New Position) | View |
| 2022-08-11 5:00 pm Purchase | 13D | Adicet Bio, Inc. ACET | Carlyle Group Inc. CG | 2,152,959 5.4% | 2,152,959 (New Position) | View |
| 2022-08-11 4:58 pm Purchase | 13D | NuCana plc NCNA | Carlyle Group Inc. CG | 3,353,134 6.4% | 3,353,134 (New Position) | View |
| 2022-08-11 4:56 pm Purchase | 13D | Soleno Therapeutics, Inc. SLNO | Carlyle Group Inc. CG | 18,368,564 15.3% | 18,368,564 (New Position) | View |
| 2022-08-11 4:55 pm Purchase | 13D | eFFECTOR Therapeutics, Inc. EFTR | Carlyle Group Inc. CG | 4,829,891 11.7% | 4,829,891 (New Position) | View |
| 2022-08-11 4:52 pm Purchase | 13D | Reneo Pharmaceuticals, Inc. RPHM | Carlyle Group Inc. CG | 2,087,957 8.5% | 2,087,957 (New Position) | View |